Top
US_Flag An official website of the United States government Here's how you know
GOV

The .gov means it's official.

Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

LOCK

The site is secure.

The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

 
U.S. Food & Drug Administration
Continuing Education and Accreditation
Division of Learning and Organizational Development
Center for Drug Evaluation and Research
Activity Outline
Topics in Public Health: Promoting the USPHS Mission Through Tobacco Cessation: Ask-Advise-Refer
November 15, 2024
Webinar

Activity Coordinators:
Amy Ramanadham (Amy.Ramanadham@fda.hhs.gov),  Jessica Voqui (Jessica.Voqui@fda.hhs.gov),  Mavis Darkwah (Mavis.Darkwah@fda.hhs.gov),  Ruby Leong (Ruby.Leong@fda.hhs.gov)
Series Description

This series will educate PHS health professionals about topics that are pertinent to their roles within the various agencies within the Department of Health and Human Services and other Public Health Service agencies by presenting topics that directly relate to the HHS Strategic Plan, the Secretary's Strategic Initiatives, current topics for DHHS OPDIVs who utilize PHS health professionals, and/or other topics directly related to the advancement of public health.

Lecture Description
This training will provide healthcare professionals, both in clinical and non-clinical roles, with the skills to perform brief, evidence-based tobacco cessation interventions. The presentation will cover the epidemiology tobacco use, negative consequences of smoking, the role of addiction in tobacco use, and review evidence-based interventions.
References
  • Benowitz NL. (2010). Nicotine addiction. N Engl J Med 362:2295–2303.
  • Campaign for Tobacco-Free Kids. (2023). “State Tobacco Prevention Spending vs. Tobacco Company Marketing.” Retrieved June 12, 2023 from https://www.tobaccofreekids.org/assets/factsheets/0406.pdf.
  • Centers for Disease Control and Prevention (CDC). (2019). Tobacco product use and cessation indicators among adults—United States, 2018. MMWR 68;1013–1019.
  • Cornelius ME, Loretan CG, Jamal A, Davis Lynn BC, Mayer M, et al. Centers for Disease Control and Prevention (CDC). (2023). Tobacco product use among adults—United States, 2021. MMWR 72;475–483.
  • Benowitz NL. (2010). Nicotine addiction. N Engl J Med 362:2295–2303.
  • Campaign for Tobacco-Free Kids. (2023). “State Tobacco Prevention Spending vs. Tobacco Company Marketing.” Retrieved June 12, 2023 from https://www.tobaccofreekids.org/assets/factsheets/0406.pdf.
  • Centers for Disease Control and Prevention (CDC). (2019). Tobacco product use and cessation indicators among adults—United States, 2018. MMWR 68;1013–1019.
  • Cornelius ME, Loretan CG, Jamal A, Davis Lynn BC, Mayer M, et al. Centers for Disease Control and Prevention (CDC). (2023). Tobacco product use among adults—United States, 2021. MMWR 72;475–483.
Series Objectives
  • Increase awareness of current topics in public health
  • Help improve patient/public health outcomes
  • Help participants modify their practice within their job or deployments
Learning Objectives After completion of this activity, the participant will be able to:
  • Describe the epidemiology of tobacco use.
  • Identify at least three negative consequences of smoking cigarettes.
  • Explain the role of addiction in tobacco use.
  • State and demonstrate the abbreviated version of the 5 A’s, i.e., A-A-R
Target Audience
This activity is intended for physicians, pharmacists, and nurses.
Registration Information
Registration is complimentary; therefore refunds are not applicable. For information on how to register to attend this activity, please contact the Activity Coordinator(s) listed above.
Agenda

Lecture 1 November 15, 2024
Time Topic Speaker
2:00 - 3:00 PM EST Promoting the USPHS Mission Through Tobacco Cessation: Ask-Advise-Refer Gayle Tuckett, PharmD
Madeline Wright, PharmD
Continuing Education Accreditation
Jointly Accredited Provider
In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ICPE Credit
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.
CME
FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE
This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-24-018-L99-P for 1.00 contact hour(s).
CNE
FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).
Requirements for Receiving CE Credit

All learners claiming credit must attest to their attendance and complete all required activity evaluation(s) in the FDA CE Portal (ceportal.fda.gov) within 14 days after an activity ends. Upon completion, learners may view/print statement of credit.

Attention NABP Pharmacists and Pharmacy Technicians: The FDA CE Team will report your credit to the National Association of Boards of Pharmacy (NABP) provided you add your NABP ID and date of birth to your profile in the FDA CE Portal. The only official Statement of Credit is the one you pull from CPE Monitor®. If you do not see your credit reflected on CPE Monitor®* after 45 days of attestation, please contact FDACETeam@fda.hhs.gov.
*CPE Monitor® sets a strict 60-day limit on uploading credits.

Disclosure

Faculty
  • Tuckett, Gayle, PharmD, Senior Public Health Analyst, HRSA - nothing to disclose
  • Wright, Madeline, PharmD, Clinical Pharmacist, Cherokee Indian Hospital Authority - nothing to disclose

Planning Committee
  • Adejuwon, Adesola, PharmD, MBA, Regulatory Review Officer, FDA - nothing to disclose
  • Adeyemo, Folaremi, PharmD, Regulatory Health Project Manager, FDA - nothing to disclose
  • Birch-Smith, Postelle, PharmD, Lead CSO, FDA - nothing to disclose
  • Brodhead, LeAnn, PharmD, Health Insurance Specialist, CMS - nothing to disclose
  • Camilli, Sara, PharmD, BCPS, Associate Director, FDA/CDER/OSE/DPV II - nothing to disclose
  • Gonzalez-Mercado, Carlos, PharmD, MA, Emergency Coordinator, FDA - nothing to disclose
  • Herber, Kari, RN, Regional Program Manager, Department of Homeland Security - nothing to disclose
  • Janusziewicz, Ashlee, Pharm.D, Compounding Incidents Team Leader, FDA/CDER/OC/OUDLC - nothing to disclose
  • Radden, Erica, MD, Medical Officer, USPHS/DHS/USCG - nothing to disclose
  • Zepeda, Josephine, PharmD, BCPP, Clinical Psychiatric Pharmacist, USPHS - nothing to disclose

CE Consultation and Accreditation Team
  • Littlefield, Jr, Kenneth P., Training Specialist, FDA/CDER/OEP/DLOD - nothing to disclose
  • Bryant, Traci, M.A.T., Lead Training Specialist, FDA/CDER/OEP/DLOD - nothing to disclose
  • Wood, Sara, Accreditation Program Administrator, CECAT, FDA/CDER/OEP/DLOD - nothing to disclose
Any relationship shown above in italics has been divested within the last 24 months and is therefore considered mitigated.
All relevant financial relationships have been mitigated.